Alloreactive Effector T Cells Require the Local Formation of a Proinflammatory Environment to Allow Crosstalk and High Avidity Interaction with Nonhematopoietic Tissues to Induce GVHD Reactivity

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 9, 2012, Pages 1353-1367

  van der Zouwen, Boris ^a   Kruisselbrink, Alwine B ^a   Jordanova, Ekaterina S ^a   Rutten, Caroline E ^a   von dem Borne, Peter A ^a   Falkenburg, J H Frederik ^a   Jedema, Inge ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Cytotoxic T cell; Graft versus host disease; ICAM 1; Minor histocompatibility antigens; Skin biopsy

Indexed keywords

CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; MINOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; CELL DESTRUCTION; CELL INFILTRATION; CELL INTERACTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; KERATINOCYTE; LYMPHOCYTE ACTIVATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN BIOPSY; T LYMPHOCYTE; UPREGULATION;

ACUTE DISEASE; BIOPSY; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL MOVEMENT; CELLULAR MICROENVIRONMENT; COCULTURE TECHNIQUES; FIBROBLASTS; GENE EXPRESSION; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE ACTIVATION; MINOR HISTOCOMPATIBILITY ANTIGENS; MULTIPLE MYELOMA; PRIMARY CELL CULTURE; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84865157446     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.06.017     Document Type: Article

References (52)

1. Appelbaum F.R. The current status of hematopoietic cell transplantation. Annu Rev Med 2003, 54:491-512.
2. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
3. Falkenburg J.H., van de Corput L., Marijt E.W., Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003, 31:743-751.
4. Feng X., Hui K.M., Younes H.M., Brickner A.G. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol 2008, 29:624-632.
5. Mullally A., Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007, 109:1355-1362.
6. Irle C., Beatty P.G., Mickelson E., Thomas E.D., Hansen J.A. Alloreactive T cell responses between HLA-identical siblings. Detection of anti-minor histocompatibility T cell clones induced in vivo. Transplantation 1985, 40:329-333.
7. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003, 100:2742-2747.
8. Riddell S.R., Murata M., Bryant S., Warren E.H. Minor histocompatibility antigens-targets of graft versus leukemia responses. Int J Hematol 2002, 76(Suppl 2):155-161.
9. Riddell S.R., Berger C., Murata M., Randolph S., Warren E.H. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003, 17:153-162.
10. Dickinson A.M., Wang X.N., Sviland L., et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002, 8:410-414.
11. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
12. Goulmy E., Gratama J.W., Blokland E., Zwaan F.E., van Rood J.J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 1983, 302:159-161.
13. Randolph S.S., Gooley T.A., Warren E.H., Appelbaum F.R., Riddell S.R. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004, 103:347-352.
14. van Bergen C.A., Kester M.G., Jedema I., et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007, 109:4089-4096.
15. Van Bergen C.A., Rutten C.E., Van Der Meijden E.D., et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res 2010, 70:9073-9083.
16. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004, 4:371-380.
17. Markiewicz M., Siekiera U., Karolczyk A., et al. Immunogenic disparities of 11 minor histocompatibility antigens (mHAs) in HLA-matched unrelated allogeneic hematopoietic SCT. Bone Marrow Transplant 2009, 43:293-300.
18. Mutis T., Gillespie G., Schrama E., Falkenburg J.H., Moss P., Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999, 5:839-842.
19. Warren E.H., Fujii N., Akatsuka Y., et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010, 115:3869-3878.
20. Dustin M.L., Long E.O. Cytotoxic immunological synapses. Immunol Rev 2010, 235:24-34.
21. van der Merwe P.A. Formation and function of the immunological synapse. Curr Opin Immunol 2002, 14:293-298.
22. Makgoba M.W., Sanders M.E., Ginther Luce G.E., et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 1988, 18:637-640.
23. Suranyi M.G., Bishop G.A., Clayberger C., et al. Lymphocyte adhesion molecules in T cell-mediated lysis of human kidney cells. Kidney Int 1991, 39:312-319.
24. Symington F.W., Santos E.B. Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-gamma-treated keratinocytes. J Immunol 1991, 146:2169-2175.
25. Berg N.N., Ostergaard H.L. Characterization of intercellular adhesion molecule-1 (ICAM-1)-augmented degranulation by cytotoxic T cells. ICAM-1 and anti-CD3 must be co-localized for optimal adhesion and stimulation. J Immunol 1995, 155:1694-1702.
26. Jenkins M.R., Griffiths G.M. The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol 2010, 22:308-313.
27. Jenkinson S.R., Williams N.A., Morgan D.J. The role of intercellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. J Immunol 2005, 174:3401-3407.
28. Schmid D.A., Irving M.B., Posevitz V., et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 2010, 184:4936-4946.
29. De Bueger M., Bakker A., Van Rood J.J., Goulmy E. Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells. Eur J Immunol 1991, 21:2839-2844.
30. Lawley T.J., Kubota Y. Cell adhesion molecules and cutaneous inflammation. Semin Dermatol 1991, 10:256-259.
31. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
32. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
33. Griffioen M., van Egmond H.M., Barnby-Porritt H., et al. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica 2008, 93:1535-1543.
34. Heemskerk M.H., de Paus R.A., Lurvink E.G., et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci U S A 2001, 98:6806-6811.
35. Heemskerk M.H., Hoogeboom M., Hagedoorn R., Kester M.G., Willemze R., Falkenburg J.H. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004, 199:885-894.
36. Kloosterboer F.M., van Luxemburg-Heijs S.A., van Soest R.A., et al. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 2005, 19:83-90.
37. Meadows L., Wang W., den Haan J.M., et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997, 6:273-281.
38. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
39. Broady R., Yu J., Chow V., et al. Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood 2010, 116:5748-5751.
40. Das H., Imoto S., Murayama T., et al. Kinetic analysis of cytokine gene expression in patients with GVHD after donor lymphocyte infusion. Bone Marrow Transplant 2001, 27:373-380.
41. Anikeeva N., Somersalo K., Sims T.N., Thomas V.K., Dustin M.L., Sykulev Y. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 2005, 102:6437-6442.
42. Galocha B., López D., López de Castro J.A. Clonal heterogeneity in LFA-3 and ICAM-1 requirement for lysis by alloreactive T lymphocytes. J Immunol 1993, 150:1653-1662.
43. Rosato A., Mandruzzato S., Bronte V., et al. Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). Int J Cancer 1995, 61:355-362.
44. Gregory C.D., Murray R.J., Edwards C.F., Rickinson A.B. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med 1988, 167:1811-1824.
45. Anichini A., Mortarini R., Alberti S., Mantovani A., Parmiani G. T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int J Cancer 1993, 53:994-1001.
46. Böhmig G.A., Kovarik J., Holter W., Pohanka E., Zlabinger G.J. Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol 1994, 152:3720-3728.
47. Ferrara J.L., Cooke K.R., Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003, 78:181-187.
48. Wilhelm K., Ganesan J., Müller T., et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 2010, 16:1434-1438.
49. Auffermann-Gretzinger S., Eger L., Bornhäuser M., et al. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation 2006, 81:866-873.
50. von dem Borne P.A., Beaumont F., Starrenburg C.W., et al. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006, 91:1559-1562.
51. Falkenburg J.H., Wafelman A.R., Joosten P., et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999, 94:1201-1208.
52. Jedema I., Meij P., Steeneveld E., et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin Cancer Res 2007, 13(2 Pt 1):636-643.